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Abstract
Introduction: Accumulation of advanced glycation end products (AGEs) in joints contributes to the pathogenesis
of cartilage damage in osteoarthritis (OA). We aim to explore the potential chondroprotective effects of resveratrol
on AGEs-stimulated porcine chondrocytes and cartilage explants.
Methods: Chondrocytes were isolated from pig joints. Activation of the IB kinase (IKK)-IBa-nuclear factor-kappaB
(NF-B) and c-Jun N-terminal kinase (JNK)/extracellular signal-regulated kinase (ERK)-activator protein-1 (AP-1)
pathways was assessed by electrophoretic mobility shift assay (EMSA), Western blot and transfection assay. The
levels of inducible nitric oxide synthase (iNOS)-NO and cyclooxygenase-2 (COX-2)-prostaglandin E2 (PGE2) were
measured by Western blot, Griess reaction or ELISA. The expression and enzyme activity of matrix
metalloproteinase-13 (MMP-13) were determined by real time RT/PCR and gelatin zymography, respectively.
Results: We show that AGEs-induced expression of iNOS and COX-2 and production of NO and PGE2 were
suppressed by resveratrol. Such effects of resveratrol were likely mediated through inhibiting IKK-IBa-NF-B and
JNK/ERK-AP-1 signaling pathways induced by AGEs. By targeting these critical signaling pathways, resveratrol
decreased AGEs-stimulated expression and activity of MMP-13 and prevented AGEs-mediated destruction of
collagen II. Histochemistry analysis further confirms that resveratrol could prevent AGEs-induced degradation of
proteoglycan and aggrecan in cartilage explants.
Conclusions: The present study reveals not only the effects and mechanisms regarding how resveratrol may
protect cartilage from AGEs-mediated damage but also the potential therapeutic benefit of resveratrol in the
treatment of OA.
Introduction
Osteoarthritis (OA) is a highly age-related inflammatory
process of joints. Aside from ageing, other factors such
as obesity, trauma, genetic predisposition and endocrine
factors contribute to the pathophysiological events
observed in the process of cartilage and joint damage
[1,2]. Although age has been recognized as the primary
risk factor for the development of OA, the association
between ageing and inflammation of the joints remains
obscure. During the ageing process, there is a phenom-
enon characterized by post-translational modification of
proteins by non-enzymatic glycation and this process
results in accumulation of advanced glycation end pro-
ducts (AGEs) in many tissues, including joints [3,4]. The
accumulated AGEs can reduce proteoglycan and col-
lagen synthesis by chondrocytes and lead to stiffness
and fragility of articular cartilage [5]. AGEs also induce
the production of matrix metalloproteases (MMPs) that
are responsible for causing cartilage degradation and
joint damage [6]. In addition to its role in the ageing
process, the receptor for AGE (RAGE) appears to play
roles in various inflammatory disorders [7].
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phenolic natural phytoalexin found in a variety of food
products, with particularly high levels in grape skin and
red wine, preserves many properties such as anti-inflam-
mation, anti-cancer, anti-oxidant and cardio-protection
[8-10]. Although limited clinical evidence is available in
OA, the anti-inflammatory properties of resveratrol have
been shown to suppress anterior cruciate ligament
transaction-induced experimental OA in rabbits [11].
Recent studies demonstrate that resveratrol can inhibit
interleukin-1 (IL-1)-induced expression of COX-2 and
production of PGE2 through suppressing NF-Ba c t i v i t y
in human chondrocytes [12]. Additionally, resveratrol is
capable via, in part, its anti-oxidant property of prevent-
ing IL-1-induced and p53-induced chondrocyte apopto-
sis [13,14].
The accumulated studies already suggest the patho-
genic roles of cytokines like IL-1 and tumor necrosis
factor alpha (TNF-a) in OA development [15]. Along
these cytokines-mediated inflammatory processes, the
transcription factors like NF-B and AP-1 have been
considered to play critical roles. Regarding this, the
results from other researchers and us indicate that com-
parable to both IL-1 and TNF-a, AGEs can activate NF-
B and AP-1 signaling pathways in chondrocytes
[16,17]. Furthermore, our results also indicate the criti-
cal roles of COX-2-PGE2 and iNOS-NO pathways in
AGEs-mediated damage of cartilage [17]. In this report,
we are interested in determining whether resveratrol
can be protective in AGEs-induced inflammation of
chondrocytes and damage of cartilage. The results
demonstrate that through inhibiting the activation of
several critical molecules, resveratrol effectively attenu-
ated AGEs-induced chondrocyte activation and cartilage
damage.
Materials and methods
Reagents and antibodies
Polyclonal antisera against iNOS, COX-2 and IBa were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Polyclonal anti-collagen II antibodies were
purchased from Chemicon International (Temecula, CA,
USA). The antibodies recognizing ERK, JNK, unpho-
sphorylated IKKa or phospho-IKKa/b were purchased
from Cell Signaling (Danvers, MA, USA). Resveratrol
(R5010) was purchased from Sigma-Aldrich Chemical
Company (St. Louis, MO, USA) and was prepared as a
200 mM stock concentration with ethanol. The required
concentrations of resveratrol for individual experiments
were made by further dilution of the stock preparation
with culture medium when needed. Unless otherwise
specified, the rest of the reagents were purchased from
Sigma-Aldrich Chemical Company.
Preparation of AGEs
Methylglyoxal-modified albumin, as the source of AGEs
examined in this study, was prepared as described [17].
In brief, by incubating 10 mg/ml of bovine serum albu-
min (BSA) (USB Corporation, Cleveland, OH, USA) in
phosphate-buffered saline (PBS) containing 50 mM
methylglyoxal, 0.1% sodium azide, and 1 mM phenyl-
methylsulphonyl fluoride (PMSF) at 37°C for seven days,
the crude preparation of AGEs was obtained. After dia-
lysis against PBS, the AGEs preparation was filtrated
and stored at -80°C until use. The AGEs preparation
using methylglyoxal-modified albumin contains N(epsi-
lon)-carboxyethyl-lysine (CEL) and other AGEs [18]. To
enhance the significance of this study, the AGEs pre-
paration using glycoaldehyde-modified albumin that
contains N(epsilon)-carboxymethyllysine (CML), pento-
sidine and other AGEs was also prepared according to
the report [19,20].
Isolation and culture of porcine chondrocytes
Porcine cartilage was obtained from the hind leg joints
of pigs. The preparation of chondrocytes from cartilage
was performed according to our previous report [17].
After enzymatic digestion of articular cartilage with 2
mg/ml protease in serum-free Dulbecco’sm o d i f i e d
Eagle’s medium (DMEM) containing antibiotics and 10%
fetal bovine serum (FBS), the specimens were then
digested overnight with 2 mg/ml collagenase I and 0.9
mg/ml hyaluronidase in DMEM/antibiotics. The cells
were collected, passed through a cell strainer (Beckton
Dickinson, Mountain View, CA, USA) and cultured in
DMEM containing 10% FBS and antibiotics for three to
four days before use.
Cytotoxicity analysis
Evaluation of potential cytotoxic effects of resveratral
was performed by using 3-(4,-Dimethylthiazol-2-y)-2,5-
diphenyl-tetrazolium bromide (MTT) colorimetric
assays as described [21]. In brief, chondrocytes were
incubated in the presence or absence of resveratrol for
48 h. Then, 25 μlo fM T T( 5m g / m li nH 2O) was
added, and cells were incubated at 37°C for 2 h followed
by the addition of 100 μl of lysis buffer containing 20%
sodium dodecyl sulfate and 50% dimethylformamide.
After incubation at 37°C for another 6 h, the content of
dissolved reduced MTT crystals was measured with an
ELISA reader (Dynatech, Chantilly, VA, USA).
Transfection and luciferase assays
Porcine chondrocytes were seeded one day before the
transfection experiment at a density of 3 × 10
5 cells/6-
cm dish. TransIT®-LT1 transfection reagent (Pan-vera,
Madison, WI, USA) was used to co-transfect 1.5 μg/ml
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luciferase with the internal control plasmid pTK-Renilla-
luciferase (Promega, Madison, WI, USA) at a ratio of
100:1 into cells in serum- and antibiotic-free DMEM.
Four hours after transfection, the culture medium was
replaced with fresh DMEM supplemented with 2% FBS.
For luciferase assay, total cell lysates were prepared and
the firefly luciferase activity was measured and normal-
ized to Renilla luciferase activity according to the dual
luciferase reporter system (Promega).
Measurement of NO and PGE2 concentrations
The measurement of NO release was reflected by deter-
mination of its stable end product, nitrite, in superna-
tants [17]. The Griess reaction was performed with the
concentrations of nitrite measured by a spectrophot-
ometer. In brief, an aliquot (100 μl) of culture superna-
tant was incubated with 50 μl of 0.1% sulfanilamide in
5% phosphoric acid and 50 μlo f0 . 1 %N-1-naphthyl-
ethylenediamine dihydrochloride. After 10 minutes of
incubation at room temperature, the absorbance was
measured at 550 nm wavelength with a plate reader
(Tecan, Grodig, Australia). PGE2 concentrations were
determined by ELISA according to the manufacturer’s
protocol (Cayman, Ann Arbor, MI, USA).
Western blotting
ECL Western blotting (Amersham-Pharmacia, Arlington
Heights, IL, USA) was performed as described [22].
Briefly, equal amounts of whole cellular extracts were
analyzed on 10% sodium dodecyl sulphate-polyacryla-
mide gel electrophoresis (SDS-PAGE) and transferred to
the nitrocellulose filter. For immunoblotting, the nitro-
cellulose filter was incubated with Tris-buffered saline
with 1% Triton X-100 containing 5% non-fat milk for 1
h and then blotted with antibodies against specific pro-
teins for another 2 h at room temperature. After wash-
ing with milk buffer, the filter was incubated with rabbit
anti-goat IgG or goat anti-rabbit IgG conjugated to
horseradish peroxidase at a concentration of 1:5000 for
30 minutes. The filter was incubated with the substrate
and then exposed to X-ray film (Kodak, Rochester, NY,
USA).
Nuclear extract preparation and electrophoretic mobility
shift assay (EMSA)
Nuclear extract preparation and EMSA analysis were
performed as detailed in our previous report [22]. The
oligonucleotides containing NF-B-binding site, SP-1
binding site or AP-1-binding site were purchased and
used as DNA probes. The DNA probes were radio-
labeled with (g-
32P)ATP using the T4 kinase (Promega).
For the binding reaction, the radio-labeled pr)be was
incubated with 4 μg of nuclear extracts. The binding
buffer contained 10 mM Tris-HCl (pH 7.5), 50 mM
NaCl, 0.5 mM ethylenediaminetetraacetic acid (EDTA),
1 mM dithiothreitol, 1 mM MgCl2, 4% glycerol and
2 μg poly(dI-dC). The reaction mixture was left at room
temperature to proceed with binding reaction for 20
minutes. The final reaction mixture was analyzed in a
6% non-denaturing polyacrylamide gel with 0.5 × Tris/
Borate/EDTA as an electrophoresis buffer.
Gelatin zymography
Gelatin zymography was performed according to the
description by other researchers [20,23]. The culture
supernatant (16 μl) was mixed with 4 μl buffer contain-
ing 4% SDS, 0.15 M Tris (pH 6.8), and 20% glycerol that
contains 0.05% bromophenol blue and analyzed on a
10% polyacrylamide gel with copolymerized 0.1% gelatin
(Sigma-Aldrich). The positive control of MMP-13 was
purchased (EMD Chemicals, Gibbstown, NJ, USA).
After electrophoresis, gels were washed with 2.5% Triton
X-100 for three times with 20 minutes each. After incu-
bation with the gelatinase buffer (50 mM Tris-HCl
(pH 7.6), 10 mM CaCl2, 50 mM NaCl, and 0.05% Brij-
35) at 37°C for 24 h, the gel was stained with 0.1% Coo-
massie blue, and the clear bands that indicate gelatinoly-
t i ca c t i v i t yw e r ev i s u a l i z e du n d e rt h eb a c k g r o u n do f
uniform light blue staining. The localization of MMP-13
was identified as judged by the molecular weight of the
standards and the report from other researchers [24]
under Casio Ex Z60 digital camera (Shibuy-ku, Tokyo,
Japan).
Immunoprecipitation kinase assay
This assay has been described in our previous work [22].
In brief, the whole cellular extract 50 to 100 μgw a s
incubated overnight with 5 μlo fs p e c i f i ca n t i b o d i e si n
incubation buffer containing 25 mM HEPES (pH 7.7),
300 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1%
Triton-X-100, 20 mM b-glycerophosphate, 0.1 mM
Na3VO4, 2 μM leupeptin, and 400 μM PMSF. The mix-
ture was then immunoprecipitated by the addition of
protein A beads and rotated at 4°C for 2 h. After exten-
sive wash, the beads were resuspended in 40 μlk i n a s e
buffer with addition of cold ATP (30 μM), 8 ng of sub-
strate (GST-c-Jun), and 10 μCi of (g-32P)ATP. The mix-
ture was incubated at 30°C with occasional gentle
mixing for 30 minutes. The reaction was then termi-
nated by resuspending in 1% SDS solubilizing buffer and
boiling for five minutes; then the samples were analyzed
in SDS-PAGE.
Real-time RT/PCR
Total RNA was isolated after lysing the cells by Trizol
(Invitrogen, Carlsbad, CA, USA). After reverse transcrip-
tion of RNA to cDNA, samples were subjected to PCR
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GAPDH messenger RNA (mRNA) was performed
according to the manufacturer’s instructions (CYBR
Green Master Mix, Applied BioSystems, Foster City,
CA, USA). In brief, 10 ng of cDNA was amplified in a
total volume of 20 μl consisting of 1× Master Mix and
the gene-specific primers, which were added at a final
concentration of 100 nM. The primer sequences for
both MMP-13 and GAPDH were described by other
reports [25,26]: 5′-CCA AAG GCT ACA ACT TGT
TTC TTG -3′ and 5′-TGG GTC CTT GGA GTG GTC
AA -3′(for MMP-13); 5′-TGT C AT CCA TGA CAA
CTC GG -3′ and 5′-GCC ACA GTT TCC CAG AGG
-3′ (for GAPDH). The reactions were performed for 50
cycles with 95°C for denaturation and 60°C for anneal-
ing and extension on the ABI 7300 real-time PCR sys-
tem (Applied BioSystems). The data were collected and
the fold changes in gene expression following stimula-
tion in the presence or absence of resveratrol was calcu-
lated with the following formula: fold changes =
2
−Δ Δ ( ) Ct , where Ct =C t stimulated -C tG A P D H ,a n d( C t)=
Ct stimulated -C t control.
Preparation of cartilage explants
The preparation of cartilage explants was performed
according to our previous report with mild modification
[17]. In brief, articular cartilage from the femur head of
hind limb joint of pigs was excavated by a stainless-steel
dermal-punch 3 mm in diameter (Aesculap, Tuttlingen,
Germany) and weighed. After dissection, each cartilage
explant was placed in a 24-well plate and cultured for
24 h in DMEM containing antibiotics and 10% FBS.
After resting for 72 h in serum-free DMEM, the carti-
lage explants were used for further study.
Analysis of cartilage degradation
Cartilage degradation was assessed by measuring the
amount of proteoglycan released into the culture med-
ium as described [17]. In brief, culture medium was
added to 1,9-dimethylmethylene blue (DMB) solution
(Sigma-Aldrich) in which the metachromatic dye can
bind sulfated glycosaminoglycan (GAG), a major com-
ponent of proteoglycan. The amount of the formation of
GAG-DMB complex was measured in a 96-well plate
using a plate reader (TECAN, Grödig, Austria) at a
wavelength 595 nm. The loss of GAG was calculated
and expressed as the total GAG (μg) released per mg
(wet weight) of the cartilage weight.
Safranin O staining and measurement of the aggrecan
NITEGE neoepitope
Cartilage explants were mounted in embedding medium
(Miles Laboratories, Naperville, IL, USA) and rapidly
frozen at -80°C. Serial but incontinuous microscopic
sections (7 μm) of cartilage explants were cut at -20°C
o naM i c r o mc r y o s t a ta n dm o u n t e do nS u p e r f r o s tP l u s
glass slides (Menzel-Gläser, Braunschweig, Germany).
Tissue sections were then stained with Safranin O/fast
green countered with Weigert′s iron hematoxylin to
assess the changes of proteoglycan content [17]. In par-
allel, the expression of aggrecan NITEGE neoepitope
recognized by NITEGE antibodies in tissue sections was
determined as described by other researchers [27].
Statistical analysis
When necessary, the results were expressed as mean ±
SD. Unpaired Student’s t-test was used to determine the
difference, which was considered to be significant when
P < 0.05.
Results
Resveratrol inhibited iNOS-NO and COX-2-PGE2
production in AGEs-stimulated porcine chondrocytes
Because both iNOS-NO and COX-2-PGE2 pathways are
critical in AGEs-induced cartilage damage [17], we
determined whether resveratrol could provide any pro-
tective effect through regulating these pathways. The
AGEs preparation using methylglyoxal-modified albumin
that contains CEL and other AGEs was chosen as the
stimulant [18]. When chondrocytes were pretreated with
various concentrations of resveratrol, the AGEs-induced
expression of iNOS was suppressed (Figure 1a). Mean-
while, resveratrol also inhibited AGEs-induced COX-2
expression. The concentrations of NO and PGE2, both
downstream products of iNOS and COX-2, respectively,
were measured. The results show that resveratrol inhib-
ited AGEs-induced NO and PGE2 production (Figure
1b, c). Importantly, resveratrol at a low concentration 25
μM was enough to inhibit PGE2 production (Figure 1c).
By both MTT and LDH release assays, we confirmed
that at the examined concentrations, resveratrol did not
have detectable cytotoxic effects in chondrocytes (Figure
1d and data not shown).
Resveratrol suppressed AGEs-stimulated IKK-IBa-NF-B
signaling
We next investigated the mechanisms of resveratrol-
mediated inhibition of iNOS and COX-2 in AGEs-acti-
vated chondrocytes. We focused on examining the activ-
ity of NF-B and AP-1, two families of transcription
factors that regulate the activation of iNOS and COX-2
genes and are critical in many inflammatory responses
[28,29]. Pretreatment with resveratrol resulted in a dose-
dependent inhibition of AGEs-induced DNA-binding
activity of NF-B (Figure 2a). Because the process of
IBa degradation proceeds before NF-B activation, we
examined whether resveratrol had any effect on IBa
degradation. The results show that AGEs treatment
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after treatment (Figure 2b). In the presence of resvera-
trol, there was dose-dependent reversal of the IBa
levels to a certain extent (Figure 2c). Since degradation
of IBa requires its phosphorylation by IB kinases, we
evaluated whether resveratrol could inhibit IKKa/b
activities. By Western blotting with antibodies specifi-
cally recognizing phosphorylated forms of both IKKa
and IKKb, the results reveal that AGEs effectively
induced phosphorylation of IKKa/b but had no effect
on total IKKa (Figure 2d). In the presence of resveratrol,
the levels of AGEs-induced phosphorylated forms of
IKKa/b decreased (Figure 2e). To determine whether
suppression of IKKa/b-IBa-NF-B DNA-binding activ-
ity could finally lead to decreased transcriptional activa-
tion in target genes, luciferase reporter assays were
applied. The reporter plasmid pNF-B-luciferase and
the internal control plasmid pTK-Renilla-luciferase were
co-transfected into chondrocytes. After transfection,
chondrocytes were equally distributed and were stimu-
lated with AGEs in the presence or absence of various
doses of resveratrol. Total cell lysates were collected for
luciferase activity measurement. We show that consis-
tent with suppression of DNA-binding activity, resvera-
trol effectively reduced AGEs-induced NF-B
transcriptional activity in a dose-dependent manner
(Figure 2f).
Down-regulation of AGEs-activated AP-1 signaling by
resveratrol
In parallel to its suppressive effects on NF-B activa-
tion, we demonstrated that resveratrol inhibited AGEs-
induced AP-1 DNA-binding activity (Figure 3a). As a
comparison, resveratrol did not affect SP-1 DNA-
binding activity. Since AGEs can induce activation
of both ERK and JNK but not p38 in porcine
Figure 1 Resveratrol inhibited AGEs-induced expression of iNOS and COX-2 and production of NO and PGE2. Chondrocytes 1 × 10
6/ml
were pretreated with various doses of resveratrol or the solvent (V), ethanol, for 24 h and then stimulated with 100 μg/ml AGEs for another 24
h. The expressions of iNOS and COX-2 and b-actin proteins were determined by Western blot (a). The productions of NO and PGE2 in the
culture supernatants were measured by Griess reactions or ELISA as described in Materials and Methods (b and c). Chondrocytes treated with
various concentrations of resveratrol for 48 h were collected and MTT assays were performed to determine possible drug cytotoxicity (d). The
values shown in each Western blot represented fold inductions of the densitometric intensity compared to the un-stimulated sample after
normalization to internal b-actin density. The representative data out of three independent experiments are shown. *: P < 0.05.
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had any effect on these AP-1 upstream kinase activ-
ities. The results show that AGEs-induced phosphory-
lation of ERK was noticeably suppressed by resveratrol
(Figure 3b). In addition, by immunoprecipitation
kinase assays, we demonstrated that resveratrol could
suppress JNK activity in a dose-dependent manner
(Figure 3c); however, resveratrol did not affect the
total amount of JNK. Instead, treatment with resvera-
trol effectively reduced AGEs-stimulated transcrip-
tional activity of AP-1 (Figure 3d).
Resveratrol affected AGEs-regulated MMP-13 expression
and activity and collagen II level
Different from rheumatoid arthritis, in which infiltrating
inflammatory cells and synovial pannus are responsible
for joint damage, chondrocytes by themselves are pri-
marily the cells causing cartilage damage through gener-
ating and secreting cartilage-breakdown enzymes like
MMPs. Because MMP-13, regulated by NF-Ba n d
AP-1 signaling pathways [30], is directly responsible for
damaging cartilage matrix, we examined the effects of
resveratrol on AGEs-induced MMP-13 activity. As
Figure 2 Resveratrol suppressed AGEs-stimulated NF-B signaling. Chondrocytes were cultured overnight with serum-free medium and
then pretreated with various doses of resveratrol or the solvent (V) for 24 h and then stimulated with 100 μg/ml AGEs for another 24 h. The
cells were collected and the nuclear extracts were prepared for determination of the DNA-binding activity of NF-B by EMSA (a).I n(b), the total
cell lysates from chondrocytes treated with AGEs for various time points were collected for determination of the levels of IBa by Western blot.
Similar to (B), except that the cells were pretreated or not with resveratrol before the stimulation with 100 μM AGEs for 4 h (c).I n(d), similar to
(B), the levels of phosphorylated IKKa/b and total IKKa were determined by Western blot using specific antibodies that recognize
phosphorylated IKKa/b or unphosphorylated IKKa.I n(e), similar to (D), the effects of resveratrol on the levels of phosphorylated IKKa/b and
total IKKa induced by AGEs treatment for 30 min were determined. In (f), the cells were co-transfected with 1 μg of the pNF-B-luciferase
reporter plasmid and the internal control plasmid pTK-Renilla-luciferase at a ratio of 100:1. After transfection, the cells were equally distributed for
individual conditions and then pretreated or not with different concentrations of resveratrol for 24 h and then treated with 100 μg/ml AGEs for
another 24 h. The cells were collected and the total cell lysates were prepared for luciferase activity determinations. The results were shown as
fold inductions of luciferase activity as compared to the unstimulated sample. Values are means ± standard deviations (error bars) for three
independent experiments. *: P < 0.05 compared to the AGEs-stimulated in the absence of resveratrol treatment.
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activities were suppressed by resveratrol. By quantitative
real time RT/PCR analysis, we demonstrate that resvera-
trol significantly decreased the levels of MMP-13
induced by AGEs treatment (Figure 4c). Since cartilage
collagen II is preferentially cleaved by MMP-13, we
determined whether resveratrol could affect AGEs-
mediated destruction of collagen II. As shown in Figure
4d, resveratrol treatment prevented AGEs-mediated
decreases of collagen II by Western blotting. Further-
more, as shown in Additional file 1, resveratrol also sup-
pressed the expression of iNOS and COX-2, the
production of PGE2 and NO, the DNA-binding activities
of NF-B and AP-1 as well as the enzyme activity of
MMP-13 in chondrocytes stimulated by another
preparation of AGEs using glycoaldehyde-modified albu-
min that contains CML, pentosidine and other AGEs
[19,20]. Altogether, the results indicate that resveratrol
was able to provide cartilage protection at least by
down-regulating AGEs-induced MMP expression and
enzyme activity as well as by preventing AGEs-mediated
decrease of collagen II in chondrocytes.
Resveratrol protected against AGEs-induced proteoglycan
and aggrecan degradation in cartilage explants
To further address the chondroprotective effect of
resveratrol as a reflection of its anti-inflammatory prop-
erty, we investigated whether resveratrol could regulate
AGEs-induced degradation of cartilage matrix. When
the cartilage explants were stained, a significant
Figure 3 Resveratrol suppressed AGEs-stimulated AP-1 signaling. Similar to Figure 2A, Chondrocytes pretreated with various doses of
resveratrol were stimulated with 100 μg/ml AGEs and the cells were collected and the nuclear extracts were prepared for determining DNA-
binding activity of AP-1 and SP-1 by EMSA (a). The total cell lysates from chondrocytes treated with 100 μg/ml AGEs for 4 h in the presence or
absence of pretreatment with various doses of resveratrol were prepared to measure the levels of both un-phosphorylated and phosphorylated
ERKs by Western blot (b).I n(c), cells were treated in the presence or absence of resveratrol and the total cell lysates were prepared and then
immune-precipitated with anti-JNK antibodies. The kinase assays were performed with GST-c-Jun as the substrate. The protein levels of total JNK
and b-actin determined by Western blot were presented as controls. In (d), the effects of resveratrol on AGEs-induced AP-1 transcriptional
activity were determined. The results were shown as fold inductions of luciferase activity as compared to the unstimulated sample. Values are
means ± standard deviations (error bars) for three independent experiments. *: P < 0.05 compared to the AGE-stimulated in the absence of
resveratrol treatment.
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increase of cleavage products of aggrecan (NITEGE)
became evident in AGEs-treated samples. Such findings
were successfully prevented by resveratrol treatment
(Figure 5, upper and middle panels). Consistently, we
demonstrated that treatment with resveratrol was effec-
tive to prevent AGEs-mediated release of proteoglycan
into the supernatants of culture of cartilage explants
(Figure 5, lower panel).
Discussion
Aside from pain-control and rehabilitation, there has
been no effective therapeutic regimen for joint disorders
in OA patients. One of the major reasons is because of
OA’s characteristics of long-lasting, slow-progression
and the varied-intensity of inflammation. Agents with
strong immunosuppressive effects are not good choices
in considering the potential adverse events from taking
such medications. Thus, the drug of choice for OA
should be the one that preserves modest anti-inflamma-
tory properties yet has limited or very low toxicity. The
components from food or drink consumed in our regu-
lar daily activity may be reasonable choices. We there-
fore, in this study, investigated the potential anti-
inflammatory action of resveratrol in AGEs-stimulated
chondrocytes.
AGEs derived from an array of precursor molecules
are very heterogenous in chemical structures. Three
major well-characterized AGEs, including pentosidine,
CML, and CEL all increase with age in cartilage collagen
[31]. Both the sum of these AGEs (CML, CEL and pen-
tosidine) and the AGEs fluorescence correlate signifi-
cantly with the mean degree of modification of arginine,
hydroxylysine and lysine residues in collagen [31]. The
concentrations of AGEs products are five-fold higher in
elderly OA patients than those in younger patients
Figure 4 Resveratrol suppressed AGEs-induced MMP-13 activation and prevented AGEs-mediated collagen II destruction. Chondrocytes
were pretreated with various doses of resveratrol for 24 h and then stimulated with 100 μg/ml AGEs for another 24 h. The activities of MMP-13
released into the culture supernatants were determined by gelatin zymography as described in Materials and Methods (a). The results from
three independent experiments were shown (b).I n(c), after treatment, the total cellular RNA was prepared and real time RT/PCR was applied to
measure the levels of MMP-13 mRNA. In (d), chondrocytes were pretreated with various doses of resveratrol for 24 h, stimulated with 100 μg/ml
AGEs for another 24 h and then the levels of collagen II in total cell lysates were determined by Western blot. *: P < 0.05 compared to the
AGEs-stimulated in the absence of resveratrol treatment.
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Page 8 of 13[32,33]. In persons aged 20 to 80, there is a good linear
correlation of increases of fluorescent intensities of
accumulated AGEs in cartilage and the difference some-
times can be more than 11-fold higher [31,34]. The
fluorescence intensities in AGEs at concentrations ran-
ging from 25 to 100 μg/ml were two- to six-fold higher
compared to those in BSA and therefore were close to
the conditions in aged joints of human beings (data not
shown).
When the physiological concentration of AGEs was
examined in this study, the results show that resveratrol
could suppress AGEs-induced iNOS-NO and COX-2-
PGE2 production and the mechanisms were likely
through inhibiting IKK-IBa-NF-B and JNK/ERK-AP-
1 signaling pathways. Such anti-inflammatory properties
of resveratrol could be faithfully reflected by detecting
the degradation of proteoglycan and aggrecan as well as
the suppression of proteoglycan release from cartilage
explants, the inhibition of collagen II decrease and the
attenuation of MMP expression and enzyme activity
induced by AGEs (summarized in Figure 6). This study
thus provides evidence of chondroprotective effects and
mechanisms of resveratrol as well as its potential appli-
cation in AGEs-mediated pathogenesis in OA joints.
Among the factors contributing to OA pathogenesis,
both COX-2 and iNOS play important roles [35,36].
Figure 5 Resveratrol protected against AGEs-induced degradation of proteoglycan and aggrecan. Porcine cartilage blocks were cultured
in 24-well plates and pretreated or not with 50 or 100 μM resveratrol for 24 h and then stimulated or not with 100 μg/ml AGEs for another 72
h. The retained proteoglycan in cartilage explants was monitored by Safranin O staining (upper panel). In parallel, the intensity of aggrecan
staining was examined (middle panel). Meanwhile, the release of proteoglycan into the culture medium was determined and normalized to the
cartilage weight as described in Materials and Methods (lower panel). The representative data from three independent experiments using
different donor cartilage blocks are shown. * denotes the statistical significance (P value < 0.05) as compared to the AGEs-stimulated in the
absence of resveratrol treatment.
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Page 9 of 13Several reports indicate that the inhibition of NO pro-
duction can suppress IL-1-induced chondrocyte apopto-
sis and reduce the severity of cartilage damage in
experimental OA models [37,38]. Given the evidence
that activation of the COX-2-PGE2 pathway in chondro-
cytes results in cell apoptosis, Pelletier et al. [39]
showed that the inhibition of COX-2 rescues cells from
death in experimental OA of dogs. Treatment with non-
steroidal anti-inflammatory drugs also inhibits IL-1-
induced MMP-1 and MMP-3 production in bovine
articular chondrocytes [40]. The importance of both
iNOS and COX-2 in AGEs-mediated pathologies is
further supported by our report that successful blockage
of either COX-2 or iNOS activity significantly reduces
AGEs-mediated proteoglycan release and cartilage
damage [17]. The data from Dave et al. [13] also reveal
that resveratrol suppresses IL-1b-induced COX-2-PGE2
activation and mediates anti-apoptosis effects in human
articular chondrocytes. Accordingly, the inhibition of
both COX-2-PGE2 and iNOS-NO pathways by resvera-
trol should suggest that it is a potential chondroprotec-
tive regimen.
Consistent with the effects on COX-2 and iNOS, the
AGEs-induced DNA-binding and transcriptional activity
of NF-B and AP-1, which also regulate the enhancer/
promoter regions of these two enzymes, were susceptible
to the suppression by resveratrol. In addition, the NF-B
and AP-1 upstream signaling molecules, including IKK-
IBa and ERK/JNK, were suppressed by resveratrol.
Somewhat different from its effect on IL-1-induced
Figure 6 The effects and mechanisms of resveratrol in AGEs-mediated damage of cartilage.A G E ss t i m u l a t i o na c t i v a t e db o t hN F - Ba n d
AP-1 signaling pathways. The activation of NF-B and AP-1 signaling leads to the generation of iNOS, COX-2 and MMP-13 that cause the
degradation of proteoglycan, aggrecan and collagen II, three major components of cartilage matrix, through direct and indirect mechanisms.
Along the activation of these critical pathways by AGEs, many associated events were blocked by the treatment of resveratrol as indicated.
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Page 10 of 13upstream molecules regulating NF-B activation, resever-
atrol suppressed AGEs-induced but not IL-1-induced
IKK activity [12]. These observations further distinguish
the down-stream signaling events regulated by AGEs sti-
mulation from those induced by the pro-inflammatory
cytokine IL-1. Given broad spectrums of NF-B- and
AP-1-targeted downstream events, resveratrol may exert
many more therapeutic benefits in AGEs-mediated
pathogenesis other than the evidence demonstrated in
this report. In support of this conclusion, resveratrol has
been shown to down-regulate the expression of pro-
inflammatory mediator and cytokine genes via inhibiting
NF-B signaling pathway [14]. The results from this
study also highlight the potential of examining small
molecule like JNK or ERK inhibitors as suggested by
other researchers in ageing-related disorders caused by
deposition and accumulation of AGEs [41].
In this study, we further show that aside from the sup-
pression of iNOS-NO, COX-2-PGE2, IKK-IBa-NF-B
and JNK/ERK-AP-1 signaling pathways, resveratrol
could potently inhibit the expression and enzyme activ-
ity of MMP-13. The results were consistent with earlier
studies demonstrating that the activation of MMP-13
critically requires the transcriptional activity of both NF-
B and AP-1 [30]. According to Mitchell et al. [42],
MMP-13 expression co-localizes with collagen II degra-
dation in active OA lesions and the inhibition of MMP-
13 greatly reduces collagen II degradation. In contrast,
the increased expression of MMP-13 in cartilages and
joints using tetracycline-regulated transcription in con-
junction with a cartilage-specific promoter results in
exaggerated loss of proteoglycan and cleavage of col-
lagen II in a transgenic animal model [43]. In addition
to being the most potent collagen II-degrading enzyme,
MMP-13 can degrade proteoglycan and aggrecan and
play a dual role in damaging cartilage matrix [44,45].
Altogether, the results presented in this report suggest
that the treatment with resveratrol helps to protect
against AGEs-induced degradation of cartilage compo-
nents like proteoglycan, aggrecan and collagen II.
There are two major limitations in this study. First,
the results of examining porcine chondrocytes could not
be exactly translated into those in studying human
chondrocytes although the study of choncrocytes from
different species has been frequently applied by many
researchers. Secondly, the concentrations of resveratrol
examined in this study were relatively high. A “good”
red wine contains approximately 75 μmol/L content of
resveratrol, which makes reasonable wine consumption
unlikely to reach effective anti-inflammatory concentra-
tions in plasma in human bodies [46]. Because of its
lipophilic character, resveratrol has been shown to accu-
mulate in tissues such as the heart, liver, and kidney
[47]. It is therefore concluded that long term absorption
of a sufficient quantity of resveratrol may increase the
beneficial effect of red wine on health [48]. Indeed,
in vitro approaches demonstrate that high concentra-
tions of resveratrol (10 to 100 μM) have cardioprotective
effects by inducing endothelial nitric-oxide synthase
gene expression and increasing nitric oxide levels in cul-
tured endothelial cells [46].H i g hc o n c e n t r a t i o n so f
resveratrol also inhibit interleukin-5-induced activation
of human peripheral blood eosinophils without reduc-
tion of cell viability [49]. One of the therapeutic
approaches with high concentrations of resveratrol (10
to 100 μM) in the treatment of AGEs-induced cartilage
damage may be performed through local delivery that
gains high anti-inflammatory and intra-articular concen-
trations and provides protection of cartilage from
damage by AGEs. Further studies are being performed
to investigate this possibility in OA animal models.
Conclusions
In this study, we show that aside from the suppression
of iNOS-NO, COX-2-PGE2,I K K - N F - Ba n dM A P K -
AP-1 signaling pathways, resveratrol could potently inhi-
bit MMP-13 expression. All these observed effects by
resveratrol contributed to the protection against AGE-
induced degradation of cartilage components like pro-
teoglycan, aggrecan and collagen II (Figure 6). Under-
standing the molecular mechanisms activated by
accumulated AGEs in joints and how the processes may
be modified by resveratrol could provide additional
approaches currently unavailable to slow the progression
of OA. It is also anticipated that the results from this
report will bring more in vitro and in vivo studies to
confirm the therapeutic benefits of resveratrol in
patients with OA and AGEs-mediated disorders.
Additional material
Additional file 1: Figure S1. Effects of resveratrol on chondrocytes
activated by an AGEs preparation using glycoaldehyde-modified albumin
(gAGEs) that contains N(epsilon)-carboxymethyllysine (CML), pentosidine
and other AGEs.
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